View Financial HealthWPD Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 0/6WPD Pharmaceuticals 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Jul 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$259k free cash flow). Shares are highly illiquid. Negative equity (-CA$714k). Revenue is less than US$1m. Market cap is less than US$10m (CA$579.9k market cap, or US$419.3k). Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding).공시 • May 31WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024. Location: british columbia, vancouver CanadaBoard Change • May 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Peter Novak was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Jun 16WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in fundingOn June 15, 2023, WPD Pharmaceuticals Inc. closed the transaction. Each Debenture is convertible into units at a conversion price of CAD 0.05 per Unit. Each Unit will consist of one common share and one share purchase warrant exercisable to purchase one additional common share at a price of CAD 0.05 for three years from the date of issuance of the Unit. The Debentures bear interest at the rate of 18% per annum compounded monthly until maturity and after default. The Debentures will mature on June 2, 2026. There were no finder’s fees paid in connection with the Private Placement. All securities issued in the Private Placement will be subject to a four-month hold period commencing on the closing date of the Private Placement.공시 • Jan 20WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line TherapyWPD Pharmaceuticals Inc. announced that the first patient enrolled in the Phase 1B/2 clinical trial of intravenously infused Berubicin in the treatment of adult patients with recurrent glioblastoma multiforme after failure of standard first line therapy, has received the first dosing of Berubicin. This is a very important step in Berubicin clinical development. WPD Pharmaceuticals has initiated multicenter, open-label, Phase 1B/2 efficacy and safetystudy of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy of a single arm of Berubicin treatment, administered at the recommended Phase 2 dose identified in Phase 1 studies, on the endpoint of ORR in up toapproximately 61 patients. Four polish clinical sites have been contracted for purpose of this clinical trials. A central reader will determine the radiologic responses for each patient according to m-RANO criteria. The responder criteria for this Simon's design will be based on objective response criteria defined as individual patients achieving CR or PR per m-RANO criteria within 6 months from baseline. Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin, was developed by Dr. Waldemar Priebe. Phase 1 clinical trial previously conducted by Reata Pharmaceuticals Inc. demonstrated positive responses after Berubicin treatment of brain cancer patients with one durable complete response.Is New 90 Day High Low • Jan 05New 90-day high: CA$0.31The company is up 27% from its price of CA$0.24 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.Is New 90 Day High Low • Oct 02New 90-day low: CA$0.24The company is down 41% from its price of CA$0.41 on 03 July 2020. The Canadian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 WBIO 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: WBIO 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장WPD Pharmaceuticals 배당 수익률 vs 시장WBIO의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (WBIO)n/a시장 하위 25% (CA)1.7%시장 상위 25% (CA)5.4%업계 평균 (Biotechs)2.4%분석가 예측 (WBIO) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 WBIO 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 WBIO 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 WBIO 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: WBIO 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YCA 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/08/05 14:37종가2025/05/08 00:00수익2024/09/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스WPD Pharmaceuticals Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • Jul 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$259k free cash flow). Shares are highly illiquid. Negative equity (-CA$714k). Revenue is less than US$1m. Market cap is less than US$10m (CA$579.9k market cap, or US$419.3k). Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding).
공시 • May 31WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024. Location: british columbia, vancouver Canada
Board Change • May 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Peter Novak was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Jun 16WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in fundingOn June 15, 2023, WPD Pharmaceuticals Inc. closed the transaction. Each Debenture is convertible into units at a conversion price of CAD 0.05 per Unit. Each Unit will consist of one common share and one share purchase warrant exercisable to purchase one additional common share at a price of CAD 0.05 for three years from the date of issuance of the Unit. The Debentures bear interest at the rate of 18% per annum compounded monthly until maturity and after default. The Debentures will mature on June 2, 2026. There were no finder’s fees paid in connection with the Private Placement. All securities issued in the Private Placement will be subject to a four-month hold period commencing on the closing date of the Private Placement.
공시 • Jan 20WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line TherapyWPD Pharmaceuticals Inc. announced that the first patient enrolled in the Phase 1B/2 clinical trial of intravenously infused Berubicin in the treatment of adult patients with recurrent glioblastoma multiforme after failure of standard first line therapy, has received the first dosing of Berubicin. This is a very important step in Berubicin clinical development. WPD Pharmaceuticals has initiated multicenter, open-label, Phase 1B/2 efficacy and safetystudy of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy of a single arm of Berubicin treatment, administered at the recommended Phase 2 dose identified in Phase 1 studies, on the endpoint of ORR in up toapproximately 61 patients. Four polish clinical sites have been contracted for purpose of this clinical trials. A central reader will determine the radiologic responses for each patient according to m-RANO criteria. The responder criteria for this Simon's design will be based on objective response criteria defined as individual patients achieving CR or PR per m-RANO criteria within 6 months from baseline. Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin, was developed by Dr. Waldemar Priebe. Phase 1 clinical trial previously conducted by Reata Pharmaceuticals Inc. demonstrated positive responses after Berubicin treatment of brain cancer patients with one durable complete response.
Is New 90 Day High Low • Jan 05New 90-day high: CA$0.31The company is up 27% from its price of CA$0.24 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Oct 02New 90-day low: CA$0.24The company is down 41% from its price of CA$0.41 on 03 July 2020. The Canadian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.